Study links dog and human aging biomarkers
Bottom line
Researchers with the Dog Aging Project say they’ve found one of the clearest signs yet that canine and human aging biology overlap: blood metabolites linked to earlier or later death in dogs tracked closely with mortality-associated metabolites already reported in people. The study, published in The Journals of Gerontology: Series A, analyzed plasma metabolomics data from 937 dogs in the project’s Precision Cohort and found 104 deaths over an average 2.6 years of follow-up. Across five independent human metabolomics studies, the direction of risk matched in 64% of shared metabolites, with even stronger agreement among the most mortality-associated signals. Texas A&M’s Kate Creevy, the Dog Aging Project’s chief veterinary officer, said the findings reinforce the value of companion dogs as a translational model for aging research. (stories.tamu.edu)
Why it matters: For veterinary professionals, the study adds weight to the idea that routine biologic signals in dogs may eventually help identify aging trajectories, disease risk, and intervention targets earlier than is possible in human cohorts. The researchers highlighted several shared mortality-associated metabolites tied to renal physiology, including pseudouridine, N2,N2-dimethylguanosine, homocitrulline, deoxycarnitine, and homoarginine, suggesting kidney-related aging pathways may be one place to focus next. More broadly, the Dog Aging Project’s design matters here: dogs live in human households, share environmental exposures, and age faster, which may let researchers test hypotheses about healthspan on a clinically relevant timeline for both veterinary and human medicine. (academic.oup.com)
What to watch: As the Dog Aging Project continues longitudinal follow-up, expect more work linking metabolomic and other “omic” biomarkers to specific age-related diseases, not just all-cause mortality. (academic.oup.com)
Key facts
- Study group
- 937 dogs from the Dog Aging Project Precision Cohort
- Study outcome
- 104 deaths over an average 2.6 years of follow-up
- Publication
- The Journals of Gerontology: Series A
- Comparison set
- Five independent human metabolomics studies
- Main finding
- Direction of mortality risk matched in 64% of shared metabolites
- Dog-specific result
- 23 dog plasma metabolites were significantly associated with all-cause mortality at FDR ≤ 0.05
- Shared metabolites
- Pseudouridine, N2,N2-dimethylguanosine, homocitrulline, deoxycarnitine, and homoarginine
- Biologic implication
- Shared metabolites were linked to renal function, suggesting kidney-related aging pathways
A new Dog Aging Project paper is sharpening the case for dogs as a serious model for human aging, not just a convenient analogy. In a study published in The Journals of Gerontology: Series A, investigators reported that blood metabolites associated with all-cause mortality in companion dogs are strikingly similar to those associated with mortality in humans, a finding Texas A&M and University of Washington researchers say could accelerate aging research across species. (stories.tamu.edu)
The work builds on the broader premise behind the Dog Aging Project, a U.S. community-science initiative launched in 2020 to understand how genes, lifestyle, and environment shape healthy aging in dogs and people. Federal backers, including the National Institute on Aging, have long framed companion dogs as a useful bridge between tightly controlled laboratory models and the complexity of real-world human aging because dogs share households, exposures, disease patterns, and healthcare structures with people, while aging on a much shorter timeline. (newsroom.uw.edu)
For this analysis, researchers examined plasma metabolomics in 937 dogs from the project’s Precision Cohort, a subgroup designed to reflect the broader U.S. companion-dog population across breed background, geography, sex, and sterilization status. The mortality analysis captured 104 deaths over an average follow-up of 2.6 years, compared with 8.0 to 22.5 years of follow-up in the human studies used for comparison. The paper reported 23 dog plasma metabolites significantly associated with all-cause mortality at FDR ≤ 0.05. When the team compared shared metabolites across five independent human studies, the direction of mortality risk was concordant in 64% of cases, and the dog-human hazard ratios were significantly correlated. (academic.oup.com)
The biologic story may be as important as the statistical one. Among the metabolites linked to mortality in both species, higher pseudouridine, N2,N2-dimethylguanosine, and homocitrulline, and lower deoxycarnitine and homoarginine tracked with greater risk. The authors noted that these metabolites are often associated with renal function in humans, raising the possibility that kidney-related aging physiology is one of the conserved pathways connecting metabolomic signatures and lifespan in both dogs and people. That’s still an inference, not proof of causation, but it gives the field a more concrete place to look next. (academic.oup.com)
Public comments around the paper suggest even the investigators were struck by the degree of overlap. In Texas A&M’s release, Creevy said the molecules that appear risky or protective in dogs are “very similar” to those in people, while UW Medicine quoted lead author Ben Harrison calling the cross-species agreement “shocking.” Senior author Daniel Promislow emphasized that dogs can generate aging insights far faster than human cohorts can, because longitudinal outcomes that may take decades to emerge in people can be observed in dogs within a few years. (stories.tamu.edu)
Why it matters: For veterinary professionals, this doesn’t change clinical practice tomorrow, but it does move the field closer to practical aging biomarkers that could eventually support risk stratification, preventive monitoring, and better-informed conversations with pet parents about healthspan rather than lifespan alone. It also strengthens the rationale for veterinary participation in longitudinal data collection, biospecimen programs, and comparative medicine research. If future studies tie these metabolomic patterns to specific syndromes, such as CKD, frailty, cognitive decline, or multimorbidity, clinicians could gain tools that are both biologically grounded and directly relevant to companion-animal care. (nia.nih.gov)
There’s also an industry backdrop worth noting. Veterinary business coverage has increasingly framed canine longevity as an emerging commercial and clinical category, spanning diagnostics, wearables, and therapeutics aimed at extending healthy years, not just survival. This study doesn’t validate any one product, but it does support the larger premise that measurable aging biology in dogs can be tracked, compared across populations, and potentially modified. That’s likely to keep investor, biotech, and academic attention on the space. (pmc.ncbi.nlm.nih.gov)
What to watch: The next key step is whether Dog Aging Project investigators can connect these mortality-associated metabolite patterns to discrete disease endpoints and intervention studies, using longer follow-up and additional omics layers to move from correlation toward clinically actionable aging signatures. (academic.oup.com)